RET/PTC fusions, RET/NTRK fusions, RET activating mutations, RAS point mutations, and BRAF point mutations all serve as markers in PTC, FTC, PDTC, ATC, and MTC, due to their promotion of increased MAPK activity and its downstream signaling (Prete et al. 2020). This evidence concerns the gene RET and medullary thyroid gland carcinoma.